GSK hails five-year ViiV Healthcare data on HIV treatment Cabenuva
GSK reported five-year data for ViiV Healthcare's HIV treatment Cabenuva, showing 77% of participants remained on the treatment and 94% had a last viral load of less than 50 copies per millilitre. The study's lead author and ViiV's CMO highlighted the positive results. GSK shares were up 0.3% in afternoon trading.
How this was made
The 30-second read
Why it matters
The five‑year OPERA study provides the most extensive real‑world evidence to date, reinforcing Cabenuva's efficacy and persistence.
Market read
Positive trial data could lift GSK shares and benefit the broader HIV treatment sector.
What to watch
Potential reimbursement or pricing negotiations for Cabenuva are not addressed
Background
GSK's ViiV Healthcare unit focuses on HIV therapies; Cabenuva is a long‑acting injectable combining cabotegravir and rilpivirine.
Ticker impact
GSK reported new five‑year real‑world data on ViiV Healthcare's long‑acting HIV therapy Cabenuva, showing high persistence and viral suppression rates.
likely upward pressure as the market prices in the encouraging trial results
First disclosure of robust five‑year outcomes; no prior public release of these specific figures.
Market effects
strengthens the HIV/antiretroviral sector outlook and may benefit other biotech firms developing long‑acting injectables
UK and European markets could see modest gains in pharma stocks
global investors tracking HIV treatment pipelines may adjust exposure
Counterpoint
If the market has already priced in the data, the impact could be muted
Key entities
- CompanyGSK PLC
British multinational pharmaceutical company
- Joint ventureViiV Healthcare
Specialist HIV company owned by GSK, Pfizer and Shionogi
